Colistimethate sodium: Difference between revisions
Created page with "__NOTOC__ {{Colistimethate sodium}} {{CMG}}; {{AE}} {{MM}} ==Overview== ==Category== ==US Brand Names== COLY-MYCIN M<sup>®</sup> ==FDA Package Insert== '''Colistimethat..." |
|||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{MM}} | {{CMG}}; {{AE}} {{MM}} | ||
==Overview== | ==Overview== | ||
'''Colistimethate sodium''' (polymyxin E) is a [[polymyxin]] [[antibiotic]] produced by certain strains of ''[[Bacillus polymyxa]]'' var. ''colistinus''. Colistin is a mixture of [[cyclic polypeptide]]s colistin A and B. Colistin is effective against most [[Gram-negative]] bacilli and is used as a [[polypeptide antibiotic]]. | |||
Colistimethate sodium is a decades-old drug that fell out of favor due to its [[nephrotoxicity]]. It remains one of the [[Drug of last resort|last-resort antibiotics]] for multidrug-resistant ''[[Pseudomonas aeruginosa]]'', ''[[Klebsiella pneumoniae]]'', and ''[[Acinetobacter]]''.<ref>{{cite journal | last1 = Falagas | first1 = ME | last2 = Grammatikos | first2 = AP | last3 = Michalopoulos | first3 = A | title = Potential of old-generation antibiotics to address current need for new antibiotics | url = http://www.ncbi.nlm.nih.gov/pubmed/18847400 | pmid = 18847400 | author-separator =, | journal = Expert review of anti-infective therapy | author-name-separator= | doi=10.1586/14787210.6.5.593 | volume=6 | issue=5 | year=2008 | month=October | pages=593–600}}</ref> [[NDM-1 metallo-β-lactamase]] multidrug-resistant [[Enterobacteriaceae]] have also shown susceptibility to Colistin.<ref name=Kumarasamy>{{cite journal |author=Kumarasamy ''et al.'' |last2=Toleman |first2=Mark A |last3=Walsh |first3=Timothy R |last4=Bagaria |first4=Jay |last5=Butt |first5=Fafhana |last6=Balakrishnan |first6=Ravikumar |last7=Chaudhary |first7=Uma |last8=Doumith |first8=Michel |last9=Giske |first9=Christian G |title=Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study |journal=The Lancet Infectious Diseases |volume= 10|issue= 9|pages= 597–602|year=2010 |month= |pmid= 20705517 |pmc=2933358|doi=10.1016/S1473-3099(10)70143-2 |url=}}</ref> | |||
==Category== | ==Category== | ||
Revision as of 02:19, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Colistimethate sodium (polymyxin E) is a polymyxin antibiotic produced by certain strains of Bacillus polymyxa var. colistinus. Colistin is a mixture of cyclic polypeptides colistin A and B. Colistin is effective against most Gram-negative bacilli and is used as a polypeptide antibiotic.
Colistimethate sodium is a decades-old drug that fell out of favor due to its nephrotoxicity. It remains one of the last-resort antibiotics for multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter.[1] NDM-1 metallo-β-lactamase multidrug-resistant Enterobacteriaceae have also shown susceptibility to Colistin.[2]
Category
US Brand Names
COLY-MYCIN M®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Dosage and Administration | How Supplied
Mechanism of Action
References
- ↑ Falagas, ME; Grammatikos, AP; Michalopoulos, A (2008). "Potential of old-generation antibiotics to address current need for new antibiotics". Expert review of anti-infective therapy. 6 (5): 593–600. doi:10.1586/14787210.6.5.593. PMID 18847400. Unknown parameter
|month=ignored (help); Unknown parameter|author-separator=ignored (help) - ↑ Kumarasamy; Toleman, Mark A; Walsh, Timothy R; Bagaria, Jay; Butt, Fafhana; Balakrishnan, Ravikumar; Chaudhary, Uma; Doumith, Michel; Giske, Christian G; et al. (2010). "Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study". The Lancet Infectious Diseases. 10 (9): 597–602. doi:10.1016/S1473-3099(10)70143-2. PMC 2933358. PMID 20705517.